Denosumab extended survival in lung cancer with bone metastases
Denosumab improved overall survival in persons with lung cancer and bone metastases more effectively than did zoledronic acid.
Denosumab improved overall survival in persons with lung cancer and bone metastases more effectively than did zoledronic acid.
An analysis of breath samples from patients with pulmonary nodules distinguished benign from malignant growths in a recent study.
Small cell lung cancers have high expression of PARP1; are more sensitive to PARP inhibition.
Concentrations are linked to percent reduction in non-small-cell lung tumor size and improved survival.
An increased risk of coronary artery stenosis in cancer survivors may be a long-term posttreatment effect of chest radiotherapy.
And, single nucleotide polymorphisms in various biologic pathways correlate with QOL measures.
Postoperative radiation confers no survival benefit for elderly with N2 non-small-cell lung cancer
Assay identifies which early-stage NSCLC patients are at high risk of death after surgical resection